Crucial role of 3-bromoethyl in removing the estrogenic activity of 17β-HSD1 inhibitor 16β-(m-carbamoylbenzyl)estradiol

ACS Medicinal Chemistry Letters

Volumn 2, Issue 9, 2011, Pages 678-681

  Maltais, René ^a   Ayan, Diana ^a   Poirier, Donald ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

17 hydroxysteroid dehydrogenase; cancer; enzyme inhibitor; estrogen; hormone; Steroid

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANTINEOPLASTIC AGENT; ESTRADIOL; ESTROGEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; HUMAN; IC 50; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 80052629623     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200093v     Document Type: Article

References (32)

1. Moeller, G.; Adamski, J. Integrated view on 17beta-hydroxysteroid dehydrogenase Mol. Cell. Endocrinol. 2009, 301, 7-19
2. Penning, T. M. 17β-Hydroxysteroid dehydrogenase: Inhibitors and inhibitor design Endocr.-Relat. Cancer 1996, 3, 41-56 (Pubitemid 26151990)
3. von Angerer, E. The Estrogen Receptor As a Target for Rational Drug Design; Molecular Biology Intelligence Unit, R. G. Landes Company: Austin, TX, 1995.
4. Simard, J.; Vincent, A.; Duchesne, R.; Labrie, F. Full oestrogenic activity of C19-delta 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs Mol. Cell. Endocrinol. 1988, 55, 233-242 (Pubitemid 18055213)
5. Theobald, A. J. Management of advanced breast cancer with endocrine therapy: The role of the primary healthcare team Int. J. Clin. Pract. 2000, 54, 665-669 (Pubitemid 32048072)
6. Dizerega, G. S.; Barber, D. L.; Hodgen, G. D. Endometriosis: Role of ovarian steroids in initiation, maintenance, and suppression Fertil. Steril. 1980, 33, 649-653 (Pubitemid 10059233)
7. Lanisnik Rizner, T. Estrogen metabolism and action in endometriosis Mol. Cell. Endocrinol. 2009, 307, 8-18
8. Poirier, D. Inhibitors of 17β-hydroxysteroid dehydrogenase Curr. Med. Chem. 2003, 10, 453-477
9. Day, J. M.; Tutill, H. J.; Purohit, A.; Reed, M. J. Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr.-Relat. Cancer 2008, 15, 665-692
10. Brozic, P.; Lanisnik-Risner, T.; Gobec, S. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 Curr. Med. Chem. 2008, 15, 137-150
11. Poirier, D. Advances in development of inhibitors of 17β- hydroxysteroid dehydrogenases Anticancer Agents Med. Chem. 2009, 9, 642-660
12. Poirier, D. 17β-Hydroxysteroid dehydrogenase inhibitors: A patent review Expert Opin. Ther. Patents 2010, 20, 1123-1145
13. Marchais-Oberwinkler, S.; Henn, C.; Moller, G.; Klein, T.; Negri, M.; Oster, A.; Spadaro, A.; Werth, R.; Wetzel, M.; Xu, K.; Frotscher, M.; Hartmann, R. W.; Adamski, J. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic target: Protein, structures, functions, and recent progress in inhibitor development J. Steroid Biochem. Mol. Biol. 2011, 125, 66-82
14. Poirier, D. Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase type 1 and 7: Key tools for studying and treating estrogen-dependent diseases J. Steroid Biochem. Mol. Biol. 2011, 125, 83-94
15. Lawrence, H. R.; Vicker, N.; Allan, G. M.; Smith, A; Mahon, M. F.; Tutill, H. J.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Novel and potent 17β-hydroxysteroid dehydrogenase type 1 inhibitors J. Med. Chem. 2005, 48, 2759-2762 (Pubitemid 40548090)
16. Vicker, N.; Lawrence, H. R.; Allan, G. M.; Bubert, C.; Smith, A; Tutill, H. J.; Purohit, A.; Day, J. M.; Mahon, M. F.; Reed, M. J.; Potter, B. V. L. Focused libraries of 16-substituted estrone derivatives and modified E-ring steroids: Inhibitors of 17β-hydroxysteroid dehydrogenase type 1 ChemMedChem 2006, 1, 464-481
17. Day, J. M.; Foster, P. A.; Tutill, H. J.; Parsons, M. F. C.; Newmann, S. P.; Chander, S. K.; Allan, G. M.; Lawrence, H. R.; Vicker, N.; Potter, B. V. L.; Reed, M. J.; Purohit, A. 17β-Hydroxysteroid dehydrogenase type 1, and not type 12, is a target for endocrine therapy of hormone-dependent breast cancer Int. J. Cancer 2008, 122, 1931-1940 (Pubitemid 351441181)
18. Messinger, J.; Husen, B.; Koskimies, P.; Hirvela, L.; Kallio, L.; Saarenketo, P.; Thole, H. Estrone C15 derivatives-A new class of 17β-hydroxysteroid dehydrogenase type 1 inhibitors Mol. Cell. Endocrinol. 2009, 301, 216-224
19. Husen, B.; Huhtinen, K.; Poutanen, M.; Kangas, L.; Messinger, J.; Thole, H. Evaluation of inhibitors of 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cell stably expressing the recombinant human enzyme Mol. Cell. Endocrinol. 2006, 248, 109-113
20. Husen, B.; Huhtinen, K.; Saloniemi, T.; Messinger, J.; Thole, H. H.; Poutanen, M. Human hydroxysteroid (17-β) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts Endocrinology 2006, 147, 5333-5339 (Pubitemid 44790588)
21. Laplante, Y.; Rancourt, C.; Poirier, D. Relative involvement of three 17β-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors Mol. Cell. Endocrinol. 2009, 301, 146-153
22. + breast cancer cell proliferation induced by estrone Bioorg. Med. Chem. 2008, 16, 1849-1860 (Pubitemid 351226579)
23. Fang, H.; Tong, W.; Shi, L. M.; Blair, R.; Perkins, R.; Branham, W.; Hass, B. S.; Xie, Q.; Dial, S. L.; Moland, C. L.; Sheehan, D. M. Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens Chem. Res. Toxicol. 2001, 14, 280-294 (Pubitemid 32238488)
24. Cadot, C.; Laplante, Y.; Kamal, F.; Luu-The, V.; Poirier, D. C6-(N, N -butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17β-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation Bioorg. Med. Chem. 2007, 15, 714-726 (Pubitemid 44880729)
25. Mazumdar, M.; Fournier, D.; Zhu, D. W.; Cadot, C.; Poirier, D.; Lin, S. X. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: A lead compound for breast cancer therapy Biochem. J. 2009, 10, 357-366
26. Maltais, R.; Tremblay, M. R.; Poirier, D. Solid-phase synthesis of hydroxysteroid derivatives using the diethylsilyloxy linker J. Comb. Chem. 2000, 2, 604-614
27. Sharifi, A.; Mohsenzadeh, F.; Mojtahedi, M. M.; Saidi, M. R.; Balalaie, S. Microwave-promoted transformation of nitriles to amides with aqueous sodium perborate Synth. Commun. 2001, 31, 431-434 (Pubitemid 32231825)
28. Poirier, D.; Chang, H. J.; Azzi, A.; Boivin, R. P.; Lin, S. X. Estrone and estradiol C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase Mol. Cell. Endocrinol. 2006, 27, 236-238
29. Skoda-Földes, R.; Kollàr, L.; Marinelli, F.; Arcadi, A. Direct and carbonylative vinylation of steroid triflates in the presence of homogeneous palladium catalysts Steroids 1994, 59, 691-695
30. Tian, Y. S.; Joo, J. E.; Kong, B. S.; Pham, V. T.; Lee, K. Y.; Ham, W. H. Asymmetric synthesis of (-) swainsonine J. Org. Chem. 2009, 74, 3962-3965
31. 13C NMR data Steroids 1997, 62, 674-681 (Pubitemid 27424184)
32. Duncan, L. J.; Reed, M. J. The role and proposed mechanism by which oestradiol 17beta-hydroxysteroid dehydrogenase regulates breast tumour oestrogen concentrations J. Steroid Biochem. Mol. Biol. 1995, 55, 565-572 (Pubitemid 26019341)